播洒政策"及时雨" "以前，医疗机构、科研院所的很多科研项目止步于获得发明专利、刊发学术文章，转化为医疗器械的 意识不足。近年来，随着各相关机构推进纵向课题研究，鼓励研究成果转化，'不会转'的问题变得更加 突出。"四川省药监局医疗器械注册管理处工作人员蔡云龙介绍，临床医生和技术专家在医疗器械开发 上面临知识体系差异、研发协作、法规理解等多方面困难。 这并非一时一地的挑战。临床需求是医疗器械创新的源头活水，如何让一线的创新灵感转化出医疗器 械？借助"春雨行动"，各试点省份着力破题解难。 "春雨行动"启动以来，试点省份药品监管部门主动向前一步，深入医疗机构，传递政策导向，深入探讨 医工转化面临的现实瓶颈，研究解决策略，并向临床医生抛出"橄榄枝"。 2025年6月，在北京举办的医疗器械临床研究成果转化推进会覆盖了132家三级医院、10家科研院所及50 家领军企业。会议不仅介绍相关政策，还由医疗机构代表与企业代表分享医工协同创新的实践路径，展 示从临床痛点挖掘、跨学科团队组建到技术难题攻克的全流程转化经验。 （来源：中国医药报） 转自：中国医药报 医疗器械临床研究成果转化"春雨行动"持续推进，多地药品监管部门在新一年 ...

南方医科大学珠江医院研发的SMART互动式AI认知早筛系统，有望以无创、低成本方式实现阿尔茨海 默病社区早期筛查；中山大学附属第一医院苏培强教授团队首创的动态脊柱侧弯矫正系统，有望在保障 矫形效果的同时，保留脊柱生理活动功能……这些"小而美、专而精"的项目，正是"春雨行动"激活临床 创新动能的生动体现。 （来源：中国医药报） 转自：中国医药报 2025年4月，国家药监局启动"春雨行动"。广东省药监局深入贯彻落实相关部署要求，聚焦破解临床研 究成果转化中"不愿转、不敢转、不会转"的现实难题，系统推动制度创新、机制重构与服务升级，全面 激活广东医疗器械源头创新活力。截至今年1月底，已收集400余个项目，并筛选出55个临床价值较高的 第三类医疗器械产品上报国家药监局医疗器械技术审评中心（以下简称国家药监局器审中心）。 建立"金标准"选出"金点子" "春雨行动"启动后，广东省药监局制定关于开展"春雨行动"——推进医疗器械临床研究成果转化工作的 实施方案，同步起草《春雨行动项目临床价值筛选评价参考标准（试行）》，构建临床研究成果项目收 集筛选机制，推动搭建广东临床转化平台，多维发力确保行动高效推进。 标准是筛选项目的重 ...

Group 1: Medical Device and Drug Development - The National Medical Products Administration (NMPA) held a meeting to promote the transformation of clinical research results in medical devices, summarizing the achievements of the "Spring Rain Action" and planning future work to enhance project matching and registration services [1] - Xinhua Medical announced that it received medical device registration certificates for several products, including surgical shadowless lamps and thoracic and abdominal endoscopes, which are expected to enhance the company's competitive edge [3] - Stone Pharmaceutical's new drug SYH2056, a selective 5-HT2A receptor agonist for treating depression, has received FDA approval for clinical trials in the U.S. [4] - Anke Bio's subsidiary has received acceptance for a clinical trial application for PA3-17 injection, targeting pediatric and adolescent relapsed/refractory T-cell leukemia, marking a significant step in expanding its indications [5] Group 2: Pharmaceutical Procurement and Regulation - Hebei Province initiated a centralized procurement process for 187 chemical drugs, with formal bidding starting on December 5 [2] - The Central Commission for Discipline Inspection emphasized tightening the safety measures for medical insurance funds, focusing on identifying and addressing fraud and abuse through data technology [3] Group 3: Industry Trends and Innovations - Two innovative pharmaceutical companies, Jiahe Biotech and Hansai Aitai, passed the hearing for listing on the Hong Kong Stock Exchange, highlighting a trend of capital integration in the biotech sector [6] - The World Health Organization released its first global guidelines for using GLP-1 drugs, including semaglutide, for obesity treatment, indicating a growing recognition of these drugs in global health strategies [7]

Core Viewpoint - The meeting on December 3, organized by the National Medical Products Administration, aims to advance the transformation of clinical research results in medical devices through the "Spring Rain Action" initiative, with a focus on nationwide implementation and accelerating product market entry [1] Group 1: Key Actions and Requirements - Participating pilot provinces are required to accurately grasp the key aspects of the "Spring Rain Action" [1] - There is an emphasis on strengthening policy promotion and training, as well as conducting project collection and evaluation [1] - The initiative encourages active development of categorized guidance services and project matching [1] Group 2: Collaborative Efforts and Innovation - The meeting highlights the need to improve cross-departmental collaboration mechanisms and enhance registration service capabilities [1] - It promotes innovation in medical devices driven by clinical value [1] - The goal is to transition the "Spring Rain Action" from pilot provinces to a nationwide regular operation [1]

Core Viewpoint - The meeting on December 3 emphasized the importance of advancing the clinical research results of medical devices through the "Spring Rain Action," aiming for nationwide implementation and faster product market entry [1] Group 1: Key Actions and Requirements - Participating pilot provinces are required to accurately grasp the key aspects of the "Spring Rain Action" [1] - There is a need to strengthen policy promotion and training, ensuring effective project collection and evaluation [1] - The meeting called for active development of categorized guidance services and improved project matching and coordination among departments [1] Group 2: Innovation and Market Entry - The initiative aims to enhance the capacity for registration services and promote innovation in medical devices driven by clinical value [1] - The goal is to transition the "Spring Rain Action" from pilot provinces to a regular nationwide operation, accelerating the product launch process [1]

Core Viewpoint - The "Spring Rain Action" initiative aims to promote the transformation of clinical research results in medical devices, enhancing innovation and industrialization processes in Guangdong's medical device sector [3][4]. Group 1: Policy and Implementation - The "Spring Rain Action" is a significant measure led by the National Medical Products Administration (NMPA) to facilitate the transformation of innovative medical device research results [3]. - Guangdong has established a comprehensive implementation plan for the "Spring Rain Action," which includes setting clear objectives, standards, and mechanisms for clinical research result collection and evaluation [4][5]. - The province's drug regulatory authority has emphasized the importance of early intervention and tailored support for medical device projects to streamline the approval process [5]. Group 2: Industry Status and Achievements - As of June 2025, Guangdong has 8,983 medical device production enterprises and over 1.76 million registered products, leading the nation in both categories [2]. - The province has received approval for 25 innovative drugs and 48 innovative medical devices, showcasing significant breakthroughs in the industry [2]. - Guangdong is home to 250 tertiary hospitals and 50 high-level hospitals, providing a robust platform for clinical trials and research [2]. Group 3: Collaborative Efforts and Future Directions - The training session for the "Spring Rain Action" involved over 60 representatives from various medical and research institutions, fostering collaboration across the medical, academic, and regulatory sectors [6]. - The initiative aims to create a coordinated mechanism involving multiple stakeholders to enhance the transformation of clinical research results into practical applications [6]. - The provincial drug regulatory authority plans to leverage this training as a catalyst for further collaboration and innovation in the medical device field [6].